HomeAI · summaries
Storia in 2 fonti
Akeso, Summit cancer drug confirms lung cancer survival benefit
A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Akeso, Summit cancer drug confirms lung cancer survival benefit
A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
- ·
endpoints.news
Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial
Akeso, Summit say ivonescimab hit the OS bar in China's Phase 3 HARMONi-2 trial vs. Keytruda; full data due at a future meeting.